Which complement assays and typings are necessary for the diagnosis of complement deficiency in patients with lupus erythematosus? A study of 25 patients

INTRODUCTION: Deficiencies in components of the classical pathway of complement activation are strong risk factors for lupus erythematosus (LE).Yet, it has not been addressed whether the conventional measurements of the serum hemolytic CH50 activity and antigenic concentrations of C3 and C4 are suff...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 121(2006), 2 vom: 10. Nov., Seite 198-202
1. Verfasser: Boeckler, P (VerfasserIn)
Weitere Verfasser: Meyer, A, Uring-Lambert, B, Goetz, J, Cribier, B, Hauptmann, G, Lipsker, D
Format: Aufsatz
Sprache:English
Veröffentlicht: 2006
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Evaluation Study Journal Article Complement C3 Complement C4 Histocompatibility Antigens Complement System Proteins 9007-36-7
LEADER 01000naa a22002652 4500
001 NLM165479817
003 DE-627
005 20231223104811.0
007 tu
008 231223s2006 xx ||||| 00| ||eng c
028 5 2 |a pubmed24n0552.xml 
035 |a (DE-627)NLM165479817 
035 |a (NLM)16987709 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Boeckler, P  |e verfasserin  |4 aut 
245 1 0 |a Which complement assays and typings are necessary for the diagnosis of complement deficiency in patients with lupus erythematosus? A study of 25 patients 
264 1 |c 2006 
336 |a Text  |b txt  |2 rdacontent 
337 |a ohne Hilfsmittel zu benutzen  |b n  |2 rdamedia 
338 |a Band  |b nc  |2 rdacarrier 
500 |a Date Completed 06.12.2006 
500 |a Date Revised 10.12.2019 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a INTRODUCTION: Deficiencies in components of the classical pathway of complement activation are strong risk factors for lupus erythematosus (LE).Yet, it has not been addressed whether the conventional measurements of the serum hemolytic CH50 activity and antigenic concentrations of C3 and C4 are sufficient to asses a deficiency in C4A, C4B or C2 components, the most common deficiencies associated with LE 
520 |a PATIENTS AND METHODS: In a retrospective series, we performed complement analyses in 35 patients with LE who were systematically screened for a complement deficiency. The majority of patients had cutaneous LE with mild systemic involvement and no complement consumption. Of 25 patients (72%) with complement deficiency we found 13 with a partial C4A deficiency, 2 with a complete C4A deficiency, 6 with a partial C4B deficiency, 2 with a complete C4B deficiency and 2 with a combined partial C2 and C4A deficiency 
520 |a RESULTS: The total complement activity (CH50) was decreased in only one out of two patients with complete C4B deficiency. CH50 level was found to be low-normal (35-38 U/ml(-1)) in one patient with partial C4B deficiency, one patient with complete C4B deficiency and both patients with combined partial C4A and C2 deficiency. Total C4 levels were normal in 9 out of 13 the patients with a partial C4A deficiency and in 2 out of 6 patients with a complete C4B deficiency. The antigenic concentration of C3 was low in only 1 patients with a complete C4B deficiency and within the normal range in all the others patients. Overall, 50% of the patients had normal or elevated C3, C4, and CH50 levels 
520 |a DISCUSSION: This study emphasizes that the usual measurements of CH50, C3 and C4 levels are not adequate to detect a C4 and/or C2 deficiency in patients with LE. In epidemiologic or investigative studies addressing the prevalence of complement deficiency, more elaborated diagnostic tests, such as C4 protein allotyping, C2 level measurement and genetic screening for type I C2 deficiency should also be performed 
650 4 |a Evaluation Study 
650 4 |a Journal Article 
650 7 |a Complement C3  |2 NLM 
650 7 |a Complement C4  |2 NLM 
650 7 |a Histocompatibility Antigens  |2 NLM 
650 7 |a Complement System Proteins  |2 NLM 
650 7 |a 9007-36-7  |2 NLM 
700 1 |a Meyer, A  |e verfasserin  |4 aut 
700 1 |a Uring-Lambert, B  |e verfasserin  |4 aut 
700 1 |a Goetz, J  |e verfasserin  |4 aut 
700 1 |a Cribier, B  |e verfasserin  |4 aut 
700 1 |a Hauptmann, G  |e verfasserin  |4 aut 
700 1 |a Lipsker, D  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 121(2006), 2 vom: 10. Nov., Seite 198-202  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:121  |g year:2006  |g number:2  |g day:10  |g month:11  |g pages:198-202 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 121  |j 2006  |e 2  |b 10  |c 11  |h 198-202